Business Wire

NC-LENOVO

2.5.2024 14:01:30 CEST | Business Wire | Press release

Share
Lenovo Advances Focus on Customer Security with new AI-powered Cyber Resiliency as a Service

Lenovo (HKSE: 992) (ADR: LNVGY), the global technology powerhouse, has launched its new AI-based Cyber Resiliency as a Service (CRaaS) leveraging Lenovo device telemetry and the Microsoft security software portfolio including Microsoft Copilot for Security and Defender for Endpoint. With AI offering protection at multiple levels, the new solution integrates greater visibility with cyber protection, detection, response and recovery across digital estates and devices. This benefits customers by helping them operate more securely across devices, users, apps, data, networks, and cloud services and aids business continuity in the face of attacks.

Security remains top-of-mind for business leaders due to various market and technology trends such as shift to hybrid work, increasing adoption of AI, and proliferation of data and devices In the third global annual survey of Chief Information Officers (CIOs) by Lenovo, 51% of CIOs said that cybersecurity remains a top priority for IT, and 65% said they find it challenging to address data privacy and security.

“Lenovo Cyber Resiliency as a Service helps give business leaders assurance of their entire estate via single-pane-of-glass visibility,” said Marc Wheelhouse, Chief Security Officer, Lenovo Solutions and Services Group. “Powerful integrated tool sets, AI, and automation provide efficacy in reviewing all logs, addressing all alerts, and helping to eliminate blind spots empowering users to identify, isolate, and contain threats. Lenovo CRaaS simplifies security procurement by offering a comprehensive solution that brings the full power of the Microsoft security stack and is fully managed by Lenovo.”

Adopting a cyber resiliency managed service helps improve business productivity and efficiency by offloading laborious and time-intensive tasks to free up IT staff and help reduce overhead costs. With hundreds of security tools from which to choose, many businesses are accustomed to piecing together disparate solutions to create a cohesive security architecture.

“Lenovo’s customers want broad protection and visibility across their organizations, a zero-trust approach, and automated security and compliance, all while streamlining their vendor relationships and effectively managing technology costs. Lenovo Cyber Resiliency as a Service is our comprehensive solution to help organizations effectively contend with sophisticated and frequent cyberattacks while also tackling other cybersecurity challenges like regulatory compliance and budget constraints,” Wheelhouse said.

Lenovo CRaaS is the latest offering in Lenovo’s commitment to help protect customers and their sensitive data, complementing its Security by Design practice which helps safeguard devices throughout the product development lifecycle, and Lenovo ThinkShield, which delivers advanced security features across Lenovo’s portfolio of hardware, software, and services. Other Lenovo CRaaS benefits:

  • All-inclusive, end-to-end cybersecurity protection
  • Fully integrated cybersecurity technology stack managed by Lenovo industry experts
  • Best practice critical controls

For more information regarding Lenovo’s suite of CRaaS security services visit here.

About Lenovo

Lenovo is a US$62 billion revenue global technology powerhouse, ranked #217 in the Fortune Global 500, employing 77,000 people around the world, and serving millions of customers every day in 180 markets. Focused on a bold vision to deliver Smarter Technology for All, Lenovo has built on its success as the world’s largest PC company by further expanding into growth areas that fuel the advancement of ‘New IT’ technologies (client, edge, cloud, network, and intelligence) including server, storage, mobile, software, solutions, and services. This transformation together with Lenovo’s world-changing innovation is building a more inclusive, trustworthy, and smarter future for everyone, everywhere. Lenovo is listed on the Hong Kong stock exchange under Lenovo Group Limited (HKSE: 992)(ADR: LNVGY). To find out more visit https://www.lenovo.com and read about the latest news via our StoryHub.

LENOVO and THINKSHIELD are trademarks of Lenovo. All other trademarks are the property of their respective owners. ©2024 Lenovo Group Limited.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240502796483/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse

Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe

Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release

Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye